Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays
J. Clin. Invest. Quan Li Zhen, et al. 115:3428 doi:10.1172/JCI23587 [Go to this article.]

Figure 3
The strongest IgG and IgM antiglomerular reactivities in B6.Sle1.lpr lupus sera. (A) IgG seroreactivities to various glomerular and nuclear Ags assayed in B6 (n = 12) and B6.Sle1.lpr mice (n = 15, 10 females and 5 males) are partitioned according to whether the observed reactivities in the lupus sera were stronger than 1,000 nfi (top) or 100–1,000 nfi (bottom). Among the B6 sera, there were no significant differences between genders; therefore data from B6 males and females have been pooled. P values at left compare B6.Sle1.lpr with the corresponding B6 values (P¹) and differences between gender in B6.Sle1.lpr sera (P²). *P < 0.05; **P < 0.01; ***P < 0.001. Note that the reactivity levels of B6.Sle1.lpr female sera to chromatin and dsDNA exceeded 20,000 nfi. (B) The strongest IgM seroreactivities (>300 nfi) noted in 15 B6.Sle1.lpr sera (10 females, 5 males) using glomerular proteome arrays are compared with the corresponding B6 levels (n = 12). P values at right compare the 2 strains. (C) Some of the highest fluorescence reactivities observed in B6.Sle1.lpr sera, categorized according to their IgG subclass. In similar assays, the reactivities observed in B6 control sera ranged from 20–100 nfi (data not plotted). Agg, aggrecan; CL, cardiolipin; Chr, chromatin; Col, collagen type IV; ds, dsDNA; Fib, fibrinogen IV; GBM, total glomerular lysate; Mat, Matrigel; Myo, myosin.